What are RLAY's recent SEC filings?
T. Rowe Price Investment Management, Inc. filed a Schedule 13G disclosing beneficial ownership of 17,868,157 shares, or 8.2%, of Relay Therapeutics, Inc. common stock as of September 30, 2026.
View full filing details →SoftBank Vision Fund entities filed an amended Schedule 13G reporting beneficial ownership of 21,904,963 shares, or 9.9%, of Relay Therapeutics common stock as of September 30, 2026. The filing is a passive ownership disclosure under Rule 13d-1(d).
View full filing details →Relay Therapeutics filed a routine Form 8-K cover page with the SEC on November 4, 2026, containing only standard registrant identification and security information with no substantive corporate event disclosed.
View full filing details →Relay Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, reporting 220,959,470 shares of common stock outstanding.
View full filing details →Has RLAY ever done a stock split?
No stock splits are recorded for RLAY.
What is RLAY's share float?
Get Real-Time RLAY Intelligence
SEPT X-Ray combines SEC filings with price targets, support/resistance levels, and smart money tracking — updated every 30 minutes.
Try SEPT X-Ray Free